Development of novel small molecule antiviral therapeutics for pathogens with epidemic potential[E8]

Do aviso

Call: Cluster 1 - Health (Single stage - 2027/1). Type of action: HORIZON Research and Innovation Actions. Expected Outcome: This topic aims at supporting activities that are enabling or contributing to one or several expected impacts of destination “Tackling diseases and reducing disease burden”. To that end, proposals under this topic should aim to deliver results that are directed at, tailored towards and contributing to all the following expected outcomes: The scientific and clinical communities have a better understanding of and access to experimental antivirals for the prevention and treatment of emerging or re-emerging viral infections, as well as for further clinical investigation. Candidate antiviral therapies are available to treat patients for emerging and re-emerging viral infections, increasing therapeutic options for clinical deployment in case of an epidemic or pandemic. Scope: Infectious diseases remain a major threat to health and health security in the EU and globally. Viral disease emergence is already being accelerated by climate change, and thus a proactive approach to the development of antiviral prophylactics and therapeutics in preparedness for future infectious disease outbreaks is needed. The availability of antivirals targeting conserved viral or host mechanisms would provide a critical preparedness measure against future health threats caused by (re)emerging infectious disease epidemics or pandemics, due to infectious disease epidemics or pandemics. This topic contributes to strengthening the Research and Innovation ecosystem within the EU and su…[E3]

Os detalhes do aviso aparecem como a fonte publicou. Os fatos e requisitos que extraímos estão em inglês.

• Aberto aUniversities and research. Classificado pelo SLETOR a partir das palavras do edital.
• CondiçãoEU grant rules apply: check the call conditions for who can apply, consortium rules and co-funding.[E4]

• RiscoThis is a grant, not a contract. Grants usually need a proposal against the funder's criteria, may need partners and often need co-funding.[E5]
• DesconhecidoWe read the funder's listing, not the full guidance or application forms.

1. Aberta a propostas · 29 de out. de 2026, 07:41 UTC

   The funder published the call with a future closing date.

   Alterado: status, notice type, published at (registro de origem Development of novel small molecule antiviral therapeutics for pathogens with e… (ID HORIZON-HLTH-2027-01-DISEASE-05))

2. Vista pela primeira vez · 28 de out. de 2026, 21:22 UTC

   The funder announced the call. Applications have not opened yet.

   Registro de origem: Development of novel small molecule antiviral therapeutics for pathogens with e… (ID HORIZON-HLTH-2027-01-DISEASE-05)

Cada dado desta página vem do edital do financiador. Cada item mostra o registro e o campo de onde foi lido.

1. E1

   The funder is European Commission.

   De Development of novel small molecule antiviral therapeutics for pathogens with e… (ID HORIZON-HLTH-2027-01-DISEASE-05), campo /metadata/type/0, lido 29 de out. de 2026, 07:41 UTC · fonte ↗ (abre em nova aba)

2. E2

   Proposals must be submitted by 17 Feb 2027, 01:00 Central European time (UTC+1).

   “2027-02-17T00:00:00.000+0000”

   De Development of novel small molecule antiviral therapeutics for pathogens with e… (ID HORIZON-HLTH-2027-01-DISEASE-05), campo /metadata/deadlineDate/0, lido 29 de out. de 2026, 07:41 UTC · fonte ↗ (abre em nova aba)

3. E3

   The buyer describes the requirement in the notice.

   “Expected Outcome: This topic aims at supporting activities that are enabling or contributing to one or several expected impacts of destination “Tackling diseases and reducing disease burden”. To that end, proposals under this topic should aim to deliver results that are directed…”

   De Development of novel small molecule antiviral therapeutics for pathogens with e… (ID HORIZON-HLTH-2027-01-DISEASE-05), campo /metadata/descriptionByte/0, lido 29 de out. de 2026, 07:41 UTC · fonte ↗ (abre em nova aba)

4. E4

   EU grant rules apply: check the call conditions for who can apply, consortium rules and co-funding.

   “EU call topic”

   De Development of novel small molecule antiviral therapeutics for pathogens with e… (ID HORIZON-HLTH-2027-01-DISEASE-05), campo /metadata/type/0, lido 29 de out. de 2026, 07:41 UTC · fonte ↗ (abre em nova aba)

5. E5

   This is an EU call for proposals.

   “31094502”

   De Development of novel small molecule antiviral therapeutics for pathogens with e… (ID HORIZON-HLTH-2027-01-DISEASE-05), campo /metadata/status/0, lido 29 de out. de 2026, 07:41 UTC · fonte ↗ (abre em nova aba)

6. E6

   Applications open on 29 Oct 2026.

   “2026-10-29T00:00:00.000+0000”

   De Development of novel small molecule antiviral therapeutics for pathogens with e… (ID HORIZON-HLTH-2027-01-DISEASE-05), campo /metadata/startDate/0, lido 29 de out. de 2026, 07:41 UTC · fonte ↗ (abre em nova aba)

7. E7

   The Funding & Tenders Portal gives the status as open for submission.

   De Development of novel small molecule antiviral therapeutics for pathogens with e… (ID HORIZON-HLTH-2027-01-DISEASE-05), campo /metadata/status/0, lido 29 de out. de 2026, 07:41 UTC · fonte ↗ (abre em nova aba)

8. E8

   The notice is titled "Development of novel small molecule antiviral therapeutics for pathogens with epidemic potential".

   De Development of novel small molecule antiviral therapeutics for pathogens with e… (ID HORIZON-HLTH-2027-01-DISEASE-05), campo /metadata/title/0, lido 29 de out. de 2026, 07:41 UTC · fonte ↗ (abre em nova aba)

9. E9

   The EU contribution per grant is up to EUR 11,000,000 (from EUR 3,000,000).

   De Development of novel small molecule antiviral therapeutics for pathogens with e… (ID HORIZON-HLTH-2027-01-DISEASE-05), campo /metadata/budgetOverview/0, lido 29 de out. de 2026, 07:41 UTC · fonte ↗ (abre em nova aba)

Source: EU Funding & Tenders Portal, © European Union, CC BY 4.0. SLETOR shortened and reformatted the text. Licença dos dados: Creative Commons Attribution 4.0 (European Commission) ↗ (abre em nova aba). Dados de contato pessoais dos avisos não são guardados nem exibidos.